Association between investigated single nucleotide polymorphisms with response and chemotherapy (N = 226)
| SNP | Genotype | SD/PD N (%) | CR/PR N (%) | OR (95% CI) | P | ORadj (95% CI)adj | Padj |
|---|---|---|---|---|---|---|---|
| rs11549465 | CC | 92 (62.2) | 56 (37.8) | Ref. | Ref. | ||
| CT | 31 (77.5) | 9 (22.5) | 0.48 (0.21–1.08) | 0.074 | 0.37 (0.14–0.97) | 0.044 | |
| TT | 10 (62.5) | 6 (37.5) | 0.99 (0.34–2.86) | 0.979 | 1.55 (0.48–4.98) | 0.464 | |
| CT+TT | 41 (73.2) | 15 (26.8) | 0.60 (0.31–1.18) | 0.141 | 0.60 (0.28–1.30) | 0.194 | |
| rs11549467 | GG | 126 (65.6) | 66 (34.4) | Ref. | Ref. | ||
| GA+AA | 14 (66.7) | 7 (33.3) | 0.96 (0.37–2.48) | 0.924 | 1.06 (0.38–2.98) | 0.906 | |
| rs2057482 | CC | 95 (63.3) | 55 (36.7) | Ref. | Ref. | ||
| CT | 41 (66.1) | 21 (33.9) | 0.89 (0.48–1.65) | 0.699 | 0.92 (0.45–1.85) | 0.806 | |
| TT | 7 (70.0) | 3 (30.0) | 0.74 (0.18–2.98) | 0.672 | 0.61 (0.11–3.39) | 0.574 | |
| CT+TT | 48 (66.7) | 24 (33.3) | 0.86 (0.48–1.56) | 0.627 | 0.87 (0.45–1.71) | 0.689 |
Clinical characteristics of patients with malignant mesothelioma (N = 234)
| Characteristic | Category/Unit | N (%) [N] |
|---|---|---|
| Sex | Man, N (%) | 176 (75.2) |
| Woman, N (%) | 58 (24.8) | |
| Age | Age, median (25%– 75%) | 66 (58–72) |
| Stage | I | 15 (6.4) [1] |
| II | 53 (22.7) | |
| III | 75 (32.2) | |
| IV | 62 (26.6) | |
| Peritoneal MM | 28 (12.0) | |
| Histological type | Epithelioid | 183 (78.2) |
| Biphasic | 20 (8.5) | |
| Sarcomatoid | 22 (9.4) | |
| Not specified | 9 (3.8) | |
| ECOG performance status | 0 | 15 (6.4) |
| 1 | 126 (53.8) | |
| 2 | 90 (38.5) | |
| 3 | 3 (1.3) | |
| C-reactive protein (CRP) | Median (25%–75%) | 21 (8–59) [19] |
| Asbestos exposure | No, N (%) | 60 (25.8) [1] |
| Yes, N (%) | 173 (74.2) | |
| Smoking | No, N (%) | 129 (55.6) [2] |
| Yes, N (%) | 103 (44.4) | |
| Pain | No, N (%) | 99 (43.4) [6] |
| Yes, N (%) | 129 (56.6) | |
| Weight loss | No, N (%) | 76 (34.4) [13] |
| Yes, N (%) | 145 (65.6) | |
| Type of chemotherapy | Gemcitabine/cisplatin | 152 (65.0) |
| Pemetreksed/cisplatin | 82 (35.0) | |
| Response to chemotherapy | SD+PD | 147 (65.0) [8] |
| CR+PR | 79 (35.0) | |
| Disease progression | No, N (%) | 21 (9.1) [3] |
| Yes, N (%) | 210 (90.9) | |
| Death | No, N (%) | 65 (27.8) |
| Yes, N (%) | 169 (72.2) | |
| Progression-free survival | Months, median value (25%–75%) | 7.9 (5.3–13.8) |
| Overall survival | Months, median value (25%–75%) | 18.2 (9.7–28.0) |
| Follow-up duration | Months, median valu (25%–75%) | 44.4 (20.4–75.5) |
Association between investigated polymorphisms and progression-free survival (N = 231)
| SNP | Genotype | PFS median (25–75%) | HR (95% CI) | P | HRadj (95% Cl)adj | Padj |
|---|---|---|---|---|---|---|
| rs11549465 | CC | 7.8 (5.6–13.0) | Ref. | Ref. | ||
| CT | 8.9 (5.3–16.2) | 0.92 (0.64–1.33) | 0.665 | 0.79 (0.52–1.20) | 0.271 | |
| TT | 5.6 (3.5–17.4) | 1.1 (0.69–1.90) | 0.608 | 0.98 (0.55–1.72) | 0.932 | |
| CT+TT | 8.5 (4.8–16.2) | 0.98 (0.71–1.35) | 0.912 | 0.84 (0.59–1.21) | 0.354 | |
| rs11549467 | GG | 7.7 (5.2–13.1) | Ref. | Ref. | ||
| GA+AA | 11.2 (7.7–16.0) | 0.74 (0.46–1.19) | 0.220 | 0.67 (0.40–1.11) | 0.119 | |
| rs2057482 | CC | 8.9 (5.5–16.0) | Ref. | Ref. | ||
| CT | 7.9 (5.3–12.4) | 1.21 (0.89–1.65) | 0.223 | 1.35 (0.95–1.92) | 0.099 | |
| TT | 7.6 (5.5–8.3) | 1.63 (0.83–3.21) | 0.158 | 1.41 (0.65–3.07) | 0.390 | |
| CT+TT | 7.6 (5.3–11.9) | 1.25 (0.93–1.68) | 0.131 | 1.35 (0.97–1.89) | 0.076 |
Association between investigated polymorphisms and overall survival (N = 234)
| SNP | Genotype | OS median (25%–75%) | HR (95% CI) | P | HRadj (95% CI)adj | Padj |
|---|---|---|---|---|---|---|
| rs11549465 | CC | 18.1 (9.9–28.0) | Ref. | Ref. | ||
| CT | 21.0 (6.8–29.8) | 0.85 (0.56–1.30) | 0.451 | 0.75 (0.47–1.19) | 0.217 | |
| TT | 20.3 (9.1–32.5) | 1.00 (0.56–1.77) | 0.994 | 0.85 (0.46–1.59) | 0.610 | |
| CT+TT | 21.0 (8.7–29.8) | 0.89 (0.62–1.28) | 0.542 | 0.78 (0.52–1.16) | 0.215 | |
| rsll549467 | GG | 18.1 (9.2–28.7) | Ref. | Ref. | ||
| GA+AA | 22.2 (12.6–29.6) | 0.90 (0.55–1.48) | 0.687 | 0.95 (0.56–1.60) | 0.847 | |
| rs2057482 | CC | 19.6 (9.8–27.9) | Ref. | Ref. | ||
| CT | 18.0 (9.8–29.7) | 1.07 (0.76–1.50) | 0.694 | 1.07 (0.74–1.52) | 0.729 | |
| TT | 11.6 (9.4–22.1) | 1.44 (0.70–2.95) | 0.325 | 1.43 (0.66–3.10) | 0.366 | |
| CT+TT | 15.6 (9.8–29.7) | 1.11 (0.81–1.53) | 0.529 | 1.10 (0.78–1.55) | 0.573 |